Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia.

Acute myeloid leukemia clinical trial cytarabine etoposide mitoxantrone refractory relapsed selinexor

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
04 Sep 2023
Historique:
medline: 4 9 2023
pubmed: 4 9 2023
entrez: 4 9 2023
Statut: aheadofprint

Résumé

Selinexor, an oral inhibitor of the nuclear transport protein Exportin-1, shows promising single-agent activity in clinical trials of relapsed/refractory (R/R) acute myeloid leukemia (AML) and preclinical synergy with topoisomerase (topo) IIα inhibitors. We conducted a phase 1, dose-escalation study of selinexor with mitoxantrone, etoposide, and cytarabine (MEC) in 23 patients aged < 60 years with R/R AML. Due to dose-limiting hyponatremia in 2 patients on dose level 2 (selinexor 40 mg/m

Identifiants

DOI: 10.1080/10428194.2023.2253480 PMID: 37665178
pubmed: 37665178
doi: 10.1080/10428194.2023.2253480
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-10

Auteurs

Bhavana Bhatnagar (B)

Division of Hematology and Medical Oncology, West Virginia University Cancer Institute, Wheeling Hospital, Wheeling, WV, USA.

Qiuhong Zhao (Q)

Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
The Ohio State University Comprehensive Cancer Center, Columbus, USA.

Alice S Mims (AS)

Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
The Ohio State University Comprehensive Cancer Center, Columbus, USA.

Sumithira Vasu (S)

Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
The Ohio State University Comprehensive Cancer Center, Columbus, USA.

Gregory K Behbehani (GK)

Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
The Ohio State University Comprehensive Cancer Center, Columbus, USA.

Karilyn Larkin (K)

Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
The Ohio State University Comprehensive Cancer Center, Columbus, USA.

James S Blachly (JS)

Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
The Ohio State University Comprehensive Cancer Center, Columbus, USA.

Mohamed A Badawi (MA)

Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University.

Kasey L Hill (KL)

Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University.

Kyle R Dzwigalski (KR)

Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University.

Mitch A Phelps (MA)

The Ohio State University Comprehensive Cancer Center, Columbus, USA.
Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University.

William Blum (W)

Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USA.

Rebecca B Klisovic (RB)

Department of Hematology and Medical Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.

Amy S Ruppert (AS)

Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
The Ohio State University Comprehensive Cancer Center, Columbus, USA.

Parvathi Ranganathan (P)

Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
The Ohio State University Comprehensive Cancer Center, Columbus, USA.

Alison R Walker (AR)

Moffitt Cancer Center, University of South Florida, Tampa, FL, USA.

Ramiro Garzon (R)

Huntsman Cancer Institute, University of Utah, Salt Lake City UT, USA.

Classifications MeSH